In this issue of Molecular Psychiatry, we have multiple articles that present exciting advances. Mitochondrial dysfunction is a topic that we are highlighting, and it is addressed by three articles that cover the full spectrum of research translation , from animal work, to genetics, and therapeutics. Manuel Gardea-Resendez et al. – see also commentary by Scaini & Quevedo – report that, in patients with bipolar disorder, antidepressants that increase mitochondrial energetics appear to elevate the risk of treatment-emergent mania (TEM) [2, 3]. They showed that adjusting for age, sex and BD subtype, TEM+ was more frequent with antidepressants that increased (24.7%), versus decreased (13.5%) mitochondrial energetics (OR = 2.21; p = 0.000009). Ene et al. showed that transplantation of allogenic healthy mitochondria into the medial prefrontal cortex of adolescent rats was beneficial in a rat model of schizophrenia, while detrimental in healthy control rats . Specifically, disparate initial changes in mitochondrial function and inflammatory response were associated with opposite long-lasting changes in proteome, neurotransmitter turnover, neuronal sprouting and behavior in adulthood. A similar inverse shift in mitochondrial function was also observed in human lymphoblastoid cells derived from patients with schizophrenia and healthy subjects due to the interference of the transplanted mitochondria with their intrinsic mitochondrial state. Additionally, in this issue, Crawford et al provided evidence that Golgi apparatus, endoplasmic reticulum and mitochondrial function may be implicated in Alzheimer’s disease after studying differential gene-expression and associated disrupted biological pathway analyses in postmortem brain samples of subjects with Alzheimer’s disease polygenic risk scores vs. case/controls (cerebellum/temporal cortex) . These articles advance our knowledge of the potential roles for mitochondrial dysfunction is various psychiatric disorders.
Starting from Selye’s remarkable and pioneering work, stress has been identified as a key risk factor for psychiatric disorders [6,7,8]. The neurobiology of stress is addressed in this issue by three remarkable papers. The patterns of spontaneous activity of proopiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus following exposure to chronic unpredictable stress (CUS) were studied by Fang et al. . They showed that CUS exposure increased spontaneous firing of POMC neurons in both male and female mice, attributable to reduced GABA-mediated synaptic inhibition and increased intrinsic neuronal excitability. Collectively, their results indicate that chronic stress induces both synaptic and intrinsic plasticity of POMC neurons, leading to neuronal hyperactivity. They suggest that POMC neuron dysfunction drives chronic stress-related behavioral deficits. It is well known that maternal prenatal stress causes dysfunction of the HPA axis feedback mechanism in their offspring in adulthood. In this issue, Liu et al report that telomerase reverse transcriptase (TERT) gene knockout causes hyperactivity of the HPA axis without hippocampal glucocorticoid receptor (GR) deficiency . Their study also suggests that the prenatal high level of glucocorticoid exposure-induced hypomethylation at Chr13:73764526 in the first exon of mouse Tert gene accounted for TERT deficiency in the dentate gyrus (DG) and hypothalamic–pituitary–adrenal (HPA)axis abnormality in the adult offspring. This conceptually novel work reveals a novel GR-independent mechanism underlying prenatal stress-associated HPA axis impairment, providing a new angle for understanding the mechanisms for maintaining HPA axis homeostasis. Studying young people who participated in the Philadelphia Neurodevelopmental Cohort (PNC), Wong et al provided direct evidence for a global acceleration of brain development associated with traumatic exposures in youths . With a normative model established with quantile regression, they demonstrated that high traumatic stress load was positively associated with poorer cognitive functioning and more psychopathology mediated by accelerated gray matter maturation. Furthermore, in their sample, stressor reactivity score (SRS), representing a normative functional response after controlling for traumatic stress load, was positively associated with accelerated gray matter maturation, particularly in the visual, somatomotor, limbic, and default mode networks and subcortical regions.
Neuroinflammation is addressed here by five papers. Enrico et al. used a machine learning approach on whole blood immunomarkers to identify an inflammation-associated psychosis onset subgroup . Sæther and colleagues studied patients with severe mental illnesses (SMI), such as schizophrenia (SZ) and bipolar (BD) spectrum disorders, investigating covariance patterns between inflammatory/immune-related markers and cognitive domains and further elucidate heterogeneity in a large SMI and healthy control (HC) cohort (SZ = 343, BD = 289, HC = 770) . They applied canonical correlation analysis (CCA) to identify modes of maximum covariation between a comprehensive selection of cognitive domains and inflammatory/immune markers. The application of hierarchical clustering on covariance patterns identified by the CCA revealed a high cognition-low immune dysregulation subgroup with predominantly HC (24% SZ, 45% BD, 74% HC) and a low cognition—high immune dysregulation subgroup predominantly consisting of SMI patients (76% SZ, 55% BD, 26% HC). These subgroups should be further characterized both in terms of phenotypes and genetics.
Since our inception we have published 476 articles on Alzheimer’s disease (AD), including in October 2021 an entire Special Issue dedicated to advances in AD [7, 14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64]. Three new and intriguing papers in this issue discuss neuroinflammation in Alzheimer’s disease (AD).
The relationship between AD and inflammation is complex and multipronged . Very briefly, it is known that neurodegenerative processes, including, but not limited to, AD, precipitate an inflammatory response in the brain . There is a widely accepted paradigm that the aging process is itself accompanied by a low-grade chronic up-regulation of certain pro-inflammatory responses—this was first called “inflamm-aging” (or inflammaging) by Franceshci et al. [67, 68]. In turn, central nervous system (CNS) inflammation drives the progression from the presence of amyloid plaque and tau tangles to the onset of dementia and Alzheimer’s disease [69, 70]. This has potential translational therapeutic implications. The inflammasome is a cytoplasmatic multi-protein complex that activates caspase-1 . The inflammasome contributes to inflammaging, with observed caspase 1 activation in aging . Flores et al have shown that pre-symptomatic caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging [73, 74]. There is also the added impact of infection-sepsis cognitive impairment .
Genome-wide association studies have reported genetic loci associated with the inflammatory pathway involved in AD . In this issue, Sherva et al. identified significant risk loci in African ancestry GWAS of dementia in a large military cohort . This is to date the largest GWAS of AD and dementia in individuals of African descent. Among the genes in or near suggestive or genome-wide significant associated variants, nine (CDA, SH2D5, DCBLD1, EML6, GOPC, ABCA7, ROS1, TMCO4, and TREM2) were differentially expressed in the brains of AD cases and controls. The authors suggest, among other things, that as GOPC suppresses complement attacks and inflammation and is cleaved by the γ-secretase complex in response to microbial infection, impairment of these activities in AD could reduce microglial phagocytic capacity and amyloid-β clearance. It is important to study various ethnic groups as genetic allele frequencies vary across populations . Other factors also come into play in the inflammation-AD interface. Obesity, a public global health challenge, promotes a state of systemic inflammation, hyperleptinemia, and leptin resistance that has been identified as a risk factor for AD [79,80,81,82]. The microbiome, which regulates the inflammasome, has been increasingly linked to AD [8, 83, 84]. Using positron emission tomography (PET), Leng et al. showed that neuroinflammation is independently associated with brain network dysfunction in AD .
The work of Varma et al. is of exceptional translational relevance—that team provided multiple lines of evidence showing that hydroxychloroquine lowers AD and related dementias risk and rescues molecular phenotypes related to AD . Hydroxychloroquine is a disease modifying antirheumatic drug (DMARD) that modulates immunity and which is widely used in the treatment of rheumatic diseases. Future studies should determine whether hydroxychloroquine could be part of therapeutic strategies to prevent or treat AD and related dementias. The complex but translationally important interface of multiple risk factors, neuroinflammation/inflammaging, Alzherimer’s disease, caspase1, and hydroxychloroquine is depicted in Fig. 1.
The continuum of infection-inflammation neurodegeneration is not restricted to AD. Ahn et al. showed that Helicobacter hepaticus augmentation triggers dopaminergic degeneration and motor disorders in mice with Parkinson’s disease .
In future issues, Molecular Psychiatry will continue to publish outstanding articles that advance our field.
Bornstein SR, Licinio J. Improving the efficacy of translational medicine by optimally integrating health care, academia and industry. Nat Med. 2011;17:1567–9. https://doi.org/10.1038/nm.2583.
Gardea-Resendez M, Coombes BJ, Veldic M, Tye SJ, Romo-Nava F, Ozerdem A, et al. Antidepressants that increase mitochondrial energetics may elevate risk of treatment-emergent mania. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01888-x.
Scaini G, Quevedo J. The conundrum of antidepressant use in bipolar disorder. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01930-y.
Ene HM, Karry R, Farfara D, Ben-Shachar D. Mitochondria play an essential role in the trajectory of adolescent neurodevelopment and behavior in adulthood: evidence from a schizophrenia rat model. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01865-4.
Crawford K, Leonenko G, Baker E, Grozeva D, Lan-Leung B, Holmans P, et al. Golgi apparatus, endoplasmic reticulum and mitochondrial function implicated in Alzheimer’s disease through polygenic risk and RNA sequencing. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01926-8.
Licinio J, Frost P. The neuroimmune-endocrine axis: pathophysiological implications for the central nervous system cytokines and hypothalamus-pituitary-adrenal hormone dynamics. Braz J Med Biol Res. 2000;33:1141–8. https://doi.org/10.1590/s0100-879x2000001000003.
Sternberg EM, Licinio J. Overview of neuroimmune stress interactions. Implications for susceptibility to inflammatory disease. Ann N Y Acad Sci. 1995;771:364–71. https://doi.org/10.1111/j.1749-6632.1995.tb44695.x.
Inserra A, Rogers GB, Licinio J, Wong ML. The microbiota-inflammasome hypothesis of major depression. Bioessays. 2018;40:e1800027 https://doi.org/10.1002/bies.201800027.
Fang X, Chen Y, Wang J, Zhang Z, Bai Y, Denney K, et al. Increased intrinsic and synaptic excitability of hypothalamic POMC neurons underlies chronic stress-induced behavioral deficits. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01872-5.
Liu MY, Wei LL, Zhu XH, Ding HC, Liu XH, Li H, et al. Prenatal stress modulates HPA axis homeostasis of offspring through dentate TERT independently of glucocorticoids receptor. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01898-9.
Wong TY, Moore TM, Seidlitz J, Yuen KSL, Ruparel K, Barzilay R, et al. Traumatic stress load and stressor reactivity score associated with accelerated gray matter maturation in youths indexed by normative models. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01908-w.
Enrico P, Delvecchio G, Turtulici N, Aronica R, Pigoni A, Squarcina L, et al. A machine learning approach on whole blood immunomarkers to identify an inflammation-associated psychosis onset subgroup. Mol Psychiatry. 2023. https://doi.org/10.1038/s41380-022-01911-1.
Saether LS, Ueland T, Haatveit B, Maglanoc LA, Szabo A, Djurovic S, et al. Inflammation and cognition in severe mental illness: patterns of covariation and subgroups. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01924-w.
Licinio J, Wong ML. Molecular psychiatry special issue: advances in Alzheimer’s disease. Mol Psychiatry. 2021;26:5467–70. https://doi.org/10.1038/s41380-021-01434-1.
Chen Z, Schwulst SJ, Mentis AA. APOE4-mediated Alzheimer disease and “Vascular”-“Meningeal Lymphatic” components: towards a novel therapeutic era? Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01242-7.
Chen Z, Schwulst SJ, Mentis AA. Correction: APOE4-mediated Alzheimer disease and “Vascular”-“Meningeal Lymphatic” components: towards a novel therapeutic era? Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01307-7.
Wainberg M, Luquez T, Koelle DM, Readhead B, Johnston C, Darvas M, et al. The viral hypothesis: how herpesviruses may contribute to Alzheimer’s disease. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01138-6.
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-beta pathway in Alzheimer’s Disease. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01249-0.
Krance SH, Wu CY, Zou Y, Mao H, Toufighi S, He X, et al. The complement cascade in Alzheimer’s disease: a systematic review and meta-analysis. Mol Psychiatry. 2019. https://doi.org/10.1038/s41380-019-0536-8.
Tsatsanis A, McCorkindale AN, Wong BX, Patrick E, Ryan TM, Evans RW, et al. The acute phase protein lactoferrin is a key feature of Alzheimer’s disease and predictor of Abeta burden through induction of APP amyloidogenic processing. Mol Psychiatry. 2021;26:5516–31. https://doi.org/10.1038/s41380-021-01248-1.
Park J, Choi H, Kim YD, Kim SH, Kim Y, Gwon Y, et al. Aberrant role of ALK in tau proteinopathy through autophagosomal dysregulation. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-020-01003-y.
Arroyo-Garcia LE, Isla AG, Andrade-Talavera Y, Balleza-Tapia H, Loera-Valencia R, Alvarez-Jimenez L, et al. Impaired spike-gamma coupling of area CA3 fast-spiking interneurons as the earliest functional impairment in the App(NL-G-F) mouse model of Alzheimer’s disease. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01257-0.
Sun HL, Chen SH, Yu ZY, Cheng Y, Tian DY, Fan DY, et al. Blood cell-produced amyloid-beta induces cerebral Alzheimer-type pathologies and behavioral deficits. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0842-1.
Fei X, Zhang Y, Mei Y, Yue X, Jiang W, Ai L, et al. Degradation of FA reduces Abeta neurotoxicity and Alzheimer-related phenotypes. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-00929-7.
Eysert F, Coulon A, Boscher E, Vreulx AC, Flaig A, Mendes T, et al. Correction to: Alzheimer’s genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-020-01015-8.
Eysert F, Coulon A, Boscher E, Vreulx AC, Flaig A, Mendes T, et al. Alzheimer’s genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-00926-w.
Lemoine L, Gillberg PG, Bogdanovic N, Nennesmo I, Saint-Aubert L, Viitanen M, et al. Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer’s disease variants: AbetaPParc and PSEN1DE9. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0817-2.
Ledo JH, Liebmann T, Zhang R, Chang JC, Azevedo EP, Wong E, et al. Presenilin 1 phosphorylation regulates amyloid-beta degradation by microglia. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0856-8.
Chopra N, Wang R, Maloney B, Nho K, Beck JS, Pourshafie N, et al. MicroRNA-298 reduces levels of human amyloid-beta precursor protein (APP), beta-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-019-0610-2.
Yang S, Gigout S, Molinaro A, Naito-Matsui Y, Hilton S, Foscarin S, et al. Chondroitin 6-sulphate is required for neuroplasticity and memory in ageing. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01208-9.
Ng RC, Jian M, Ma OK, Bunting M, Kwan JS, Zhou GJ, et al. Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer’s disease mouse model. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0701-0.
Morales R, Bravo-Alegria J, Moreno-Gonzalez I, Duran-Aniotz C, Gamez N, Edwards Iii G, et al. Transmission of cerebral amyloid pathology by peripheral administration of misfolded Abeta aggregates. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01150-w.
Ryu WI, Bormann MK, Shen M, Kim D, Forester B, Park Y, et al. Brain cells derived from Alzheimer’s disease patients have multiple specific innate abnormalities in energy metabolism. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01068-3.
Brookhouser N, Raman S, Frisch C, Srinivasan G, Brafman DA. APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01076-3.
Velez JI, Lopera F, Sepulveda-Falla D, Patel HR, Johar AS, Chuah A, et al. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease. Mol Psychiatry. 2016;21:916–24. https://doi.org/10.1038/mp.2015.177.
Perez MJ, Ivanyuk D, Panagiotakopoulou V, Di Napoli G, Kalb S, Brunetti D, et al. Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer’s disease-like pathology in human cerebral organoids. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0807-4.
Ghatak S, Dolatabadi N, Gao R, Wu Y, Scott H, Trudler D, et al. NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0776-7.
Alic I, Goh PA, Murray A, Portelius E, Gkanatsiou E, Gough G, et al. Correction: patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01206-x.
Alic I, Goh PA, Murray A, Portelius E, Gkanatsiou E, Gough G, et al. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0806-5.
Nitsche A, Arnold C, Ueberham U, Reiche K, Fallmann J, Hackermuller J, et al. Alzheimer-related genes show accelerated evolution. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0680-1.
DeMichele-Sweet MAA, Klei L, Creese B, Harwood JC, Weamer EA, McClain L, et al. Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01152-8.
Wagner M, Lorenz G, Volk AE, Brunet T, Edbauer D, Berutti R, et al. Clinico-genetic findings in 509 frontotemporal dementia patients. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01271-2.
Kumar A, Koistinen NA, Malarte ML, Nennesmo I, Ingelsson M, Ghetti B, et al. Astroglial tracer BU99008 detects multiple binding sites in Alzheimer’s disease brain. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01101-5.
Sala A, Nordberg A, Rodriguez-Vieitez E. Alzheimer’s Disease Neuroimaging I. Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-beta positivity. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-00950-w.
Chiotis K, Savitcheva I, Poulakis K, Saint-Aubert L, Wall A, Antoni G, et al. [(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0815-4.
Bucci M, Chiotis K, Nordberg A, Alzheimer’s Disease Neuroimaging I. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01263-2.
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, et al. APOEepsilon4 potentiates the relationship between amyloid-beta and tau pathologies. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0688-6.
Kang MS, Aliaga AA, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, et al. Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0818-1.
Calsolaro V, Matthews PM, Donat CK, Livingston NR, Femminella GD, Guedes SS, et al. Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using (11)C-BU99008 PET and its relationship with amyloid load. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01193-z.
Moriguchi S, Takahata K, Shimada H, Kubota M, Kitamura S, Kimura Y, et al. Excess tau PET ligand retention in elderly patients with major depressive disorder. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0766-9.
Monteiro-Fernandes D, Silva JM, Soares-Cunha C, Dalla C, Kokras N, Arnaud F, et al. Allosteric modulation of AMPA receptors counteracts Tau-related excitotoxic synaptic signaling and memory deficits in stress- and Abeta-evoked hippocampal pathology. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0794-5.
Wu J, Carlock C, Shim J, Moreno-Gonzalez I, Glass W, 2nd, Ross A, et al. Requirement of brain interleukin33 for aquaporin4 expression in astrocytes and glymphatic drainage of abnormal tau. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-020-00992-0.
Xu Y, Du S, Marsh JA, Horie K, Sato C, Ballabio A, et al. TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0738-0.
Dickstein DL, De Gasperi R, Gama Sosa MA, Perez-Garcia G, Short JA, Sosa H, et al. Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0674-z.
Thompson AGB, Anastasiadis P, Druyeh R, Whitworth I, Nayak A, Nihat A, et al. Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01045-w.
O’Connor A, Karikari TK, Poole T, Ashton NJ, Lantero Rodriguez J, Khatun A, et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0838-x.
Xia Y, Wang ZH, Zhang J, Liu X, Yu SP, Ye KX, et al. C/EBPbeta is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer’s disease. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-00956-4.
Pentz R, Iulita MF, Ducatenzeiler A, Bennett DA, Cuello AC. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0797-2.
Beydoun MA, Beydoun HA, Weiss J, Hossain S, El-Hajj ZW, Zonderman AB. Helicobacter pylori, periodontal pathogens, and their interactive association with incident all-cause and Alzheimer’s disease dementia in a large national survey. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0736-2.
Panitch R, Hu J, Chung J, Zhu C, Meng G, Xia W, et al. Integrative brain transcriptome analysis links complement component 4 and HSPA2 to the APOE epsilon2 protective effect in Alzheimer disease. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01266-z.
Ou YN, Yang YX, Deng YT, Zhang C, Hu H, Wu BS, et al. Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01251-6.
Tian DY, Cheng Y, Zhuang ZQ, He CY, Pan QG, Tang MZ, et al. Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer’s disease. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01073-6.
Stocker H, Perna L, Weigl K, Mollers T, Schottker B, Thomsen H, et al. Correction: Prediction of clinical diagnosis of Alzheimer’s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01311-x.
Stocker H, Perna L, Weigl K, Mollers T, Schottker B, Thomsen H, et al. Prediction of clinical diagnosis of Alzheimer’s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0764-y.
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405. https://doi.org/10.1016/S1474-4422(15)70016-5.
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement. 2018;4:575–90. https://doi.org/10.1016/j.trci.2018.06.014.
Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x.
Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, et al. Inflammaging as a prodrome to Alzheimer’s disease. J Neuroinflamm. 2008;5:51 https://doi.org/10.1186/1742-2094-5-51.
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27:1592–9. https://doi.org/10.1038/s41591-021-01456-w.
Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Publisher Correction: Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27:2048–9. https://doi.org/10.1038/s41591-021-01568-3.
Mastronardi C, Whelan F, Yildiz OA, Hannestad J, Elashoff D, McCann SM, et al. Caspase 1 deficiency reduces inflammation-induced brain transcription. Proc Natl Acad Sci USA. 2007;104:7205–10. https://doi.org/10.1073/pnas.0701366104.
Mejias NH, Martinez CC, Stephens ME, de Rivero Vaccari JP. Contribution of the inflammasome to inflammaging. J Inflamm. 2018;15:23 https://doi.org/10.1186/s12950-018-0198-3.
Flores J, Noel A, Foveau B, Beauchet O, LeBlanc AC. Publisher Correction: Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun. 2021;12:2271 https://doi.org/10.1038/s41467-021-22789-7.
Flores J, Noel A, Foveau B, Beauchet O, LeBlanc AC. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging. Nat Commun. 2020;11:4571 https://doi.org/10.1038/s41467-020-18405-9.
Giridharan VV, Generoso JS, Lence L, Candiotto G, Streck E, Petronilho F, et al. A crosstalk between gut and brain in sepsis-induced cognitive decline. J Neuroinflamm. 2022;19:114 https://doi.org/10.1186/s12974-022-02472-4.
Dos Santos LR, Pimassoni LHS, Sena GGS, Camporez D, Belcavello L, Trancozo M, et al. Validating GWAS variants from microglial genes implicated in Alzheimer’s disease. J Mol Neurosci. 2017;62:215–21. https://doi.org/10.1007/s12031-017-0928-7.
Sherva R, Zhang R, Sahelijo N, Jun G, Anglin T, Chanfreau C, et al. African ancestry GWAS of dementia in a large military cohort identifies significant risk loci. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01890-3.
LLerena A, Dorado P, O’Kirwan F, Jepson R, Licinio J, Wong ML. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J. 2004;4:403–6. https://doi.org/10.1038/sj.tpj.6500278.
Flores-Cordero JA, Perez-Perez A, Jimenez-Cortegana C, Alba G, Flores-Barragan A, Sanchez-Margalet V. Obesity as a risk factor for dementia and Alzheimer’s disease: the role of leptin. Int J Mol Sci. 2022;23:5202 https://doi.org/10.3390/ijms23095202.
Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK, et al. Leptin replacement improves cognitive development. PLoS ONE. 2008;3:e3098 https://doi.org/10.1371/journal.pone.0003098.
Paz-Filho G, Wong ML, Licinio J. The procognitive effects of leptin in the brain and their clinical implications. Int J Clin Pract. 2010;64:1808–12.
Schwarz PE, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, et al. The Metabolic Syndrome - a global challenge for prevention. Horm Metab Res. 2007;39:777–80. https://doi.org/10.1055/s-2007-990312.
Bou Zerdan M, Hebbo E, Hijazi A, El Gemayel M, Nasr J, Nasr D, et al. The gut microbiome and Alzheimer’s disease: a growing relationship. Curr Alzheimer Res. 2022. https://doi.org/10.2174/1567205020666221227090125.
Wong ML, Inserra A, Lewis MD, Mastronardi CA, Leong L, Choo J, et al. Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Mol Psychiatry. 2016;21:797–805. https://doi.org/10.1038/mp.2016.46.
Leng F, Hinz R, Gentleman S, Hampshire A, Dani M, Brooks DJ, et al. Neuroinflammation is independently associated with brain network dysfunction in Alzheimer’s disease. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01878-z.
Varma VR, Desai RJ, Navakkode S, Wong LW, Anerillas C, Loeffler T, et al. Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01912-0.
Ahn EH, Liu X, Alam AM, Kang SS, Ye K. Helicobacter hepaticus augmentation triggers Dopaminergic degeneration and motor disorders in mice with Parkinson’s disease. Mol Psychiatry. 2022. https://doi.org/10.1038/s41380-022-01910-2.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Licinio, J., Wong, ML. Advances in Molecular Psychiatry – March 2023: mitochondrial function, stress, neuroinflammation – bipolar disorder, psychosis, and Alzheimer’s disease. Mol Psychiatry 28, 968–971 (2023). https://doi.org/10.1038/s41380-023-01968-6